arthritis psoriatica psoriatic arthropathy
Conditions
Interventions
None listed
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Psoriatic Arthritis group; 1.Age; 18-75 years 2.Joint inflammation of one or both knees due psoriatic artritis. 3.Patients require systemic treatment. 4.have failed to respond to, or have a contraindication for cyclosporine and other DMARDS exept MTX.;Psoriasis group; 1.Age; 18-75 years 2.Patients have psoriasis and a severity index (PASI) of 10 or more then 10 and/or Body Surface Area (BSA) of 10 or more then 10 and/or PASI of 8 or less then 8 together with skindex of 35 or more then 35. 3. Patients have psoriasis in their history for at least 10 years. 4. Patients have no signs of joint inflammation, nor in their history. 5.Patients require systemic treatment. 6.Patients have failed to respond to, or have a contraindication for cyclosporine and other DMARDS exept MTX.
Exclusion criteria
Exclusion criteria: Pregnancy and lactation- active (or chronic) infections including Hepatitis B and C viral infections, HIV and tuberculosis- Malignancy in last 10 years, exept BCC and cervical insitu cancer- treatment with a biological stopped because of inefficacy, contraindication or serious adverse events, after biological therapy for minimal 12 weeks-demyelinating disease-congestive heart failure-allergies and hypersensitivities to potential anti-rheumatic drugs or their ingredients-any live virus or bacterial vaccination within 3 months- severe liver function disorders > 2 timesand/or kidney function disorders > 1,5 times upper limits of the reference values.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Typing of pathogenic T cell population in skin an joints; 1.T-cell receptor (TCR-G) profile. 2.Gene expression profile. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Effects of anti-arthritic therapy on pathogenic T cells. | — |
Countries
Netherlands
Outcome results
None listed